Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Rescigno P, Porta N, Finneran L, Riisnaes R, Figueiredo I, Carreira S, Flohr P, Miranda S, Bertan C, Ferreira A, Crespo M, Rodrigues DN, Gurel B, Nobes J, Crabb S, Malik Z, Ralph C, McGovern U, Hoskin P, Jones RJ, Birtle A, Gale J, Sankey P, Jain S, McLaren D, Chadwick E, Espinasse A, Hall E, de Bono J. Rescigno P, et al. Among authors: porta n. Eur J Cancer. 2024 May 8;205:114103. doi: 10.1016/j.ejca.2024.114103. Online ahead of print. Eur J Cancer. 2024. PMID: 38729054 Free article.
Wastewater Surveillance of US Coast Guard Installations and Seagoing Military Vessels to Mitigate the Risk of COVID-19 Outbreaks, March 2021-August 2022.
Hall GJ, Page EJ, Rhee M, Hay C, Krause A, Langenbacher E, Ruth A, Grenier S, Duran AP, Kamara I, Iskander JK, Alsayyid F, Thomas DL, Bock E, Porta N, Pharo J, Osterink BA, Zelmanowitz S, Fleischmann CM, Liyanage D, Gray JP. Hall GJ, et al. Among authors: porta n. Public Health Rep. 2024 Apr 1:333549241236644. doi: 10.1177/00333549241236644. Online ahead of print. Public Health Rep. 2024. PMID: 38561999
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial.
Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, Stamp G, Thompson L, Edmonds K, Sarker S, Banerji J, Lorigan P, Evans TRJ, Corrie P, Marshall E, Middleton MR, Nathan P, Nicholson S, Ottensmeier C, Plummer R, Bliss J, Valpione S, Turajlic S. Larkin J, et al. Among authors: porta n. Cell Rep Med. 2024 Mar 19;5(3):101435. doi: 10.1016/j.xcrm.2024.101435. Epub 2024 Feb 27. Cell Rep Med. 2024. PMID: 38417447 Free PMC article. Clinical Trial.
A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial.
Smith TAD, West CML, Joseph N, Lane B, Irlam-Jones J, More E, Mistry H, Reeves KJ, Song YP, Reardon M, Hoskin PJ, Hussain SA, Denley H, Hall E, Porta N, Huddart RA, James ND, Choudhury A. Smith TAD, et al. Among authors: porta n. EBioMedicine. 2024 Mar;101:105032. doi: 10.1016/j.ebiom.2024.105032. Epub 2024 Feb 21. EBioMedicine. 2024. PMID: 38387404 Free PMC article. Clinical Trial.
Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study.
Keaveney S, Dragan A, Rata M, Blackledge M, Scurr E, Winfield JM, Shur J, Koh DM, Porta N, Candito A, King A, Rennie W, Gaba S, Suresh P, Malcolm P, Davis A, Nilak A, Shah A, Gandhi S, Albrizio M, Drury A, Pratt G, Cook G, Roberts S, Jenner M, Brown S, Kaiser M, Messiou C. Keaveney S, et al. Among authors: porta n. Insights Imaging. 2023 Oct 15;14(1):170. doi: 10.1186/s13244-023-01498-3. Insights Imaging. 2023. PMID: 37840055 Free PMC article.
Clinical trial designs for evaluating and exploiting cancer evolution.
Ingles Garces AH, Porta N, Graham TA, Banerji U. Ingles Garces AH, et al. Among authors: porta n. Cancer Treat Rev. 2023 Jul;118:102583. doi: 10.1016/j.ctrv.2023.102583. Epub 2023 May 24. Cancer Treat Rev. 2023. PMID: 37331179 Free article. Review.
237 results